NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“
Company” or “
NurExone”), a
biopharmaceutical company developing biologically-guided exosome
therapy for patients with traumatic spinal cord injuries, is
pleased to share several updates.
The collaborative agreement between NurExone and
Inteligex Inc. (“Inteligex”), announced in October
2023, to expand the Company’s portfolio, is now officially
underway. This collaboration, aimed at combining Inteligex’s more
than twenty years of experience in cell-based therapies and
NurExone’s innovative exosome platform to develop therapies for
patients with chronic spinal cord injuries, was approved for grant
funding, to be disbursed over the course of the next two years, by
the Israel-Canada bilateral Eureka program.
Dr. Lior Shaltiel, CEO of NurExone, expressed
his excitement about the kick-off of this project stating, “This
collaboration reiterates the importance and utility of the
ExoTherapy platform in developing drug delivery systems of the
future. As part of this collaboration, we will use our platform to
produce and load exosomes from Inteligex’s cell line to deliver
combination regenerative therapy for Spinal Cord Injury (SCI)
patients. This win-win collaboration will expand our potential
markets and is in line with our belief of patient, first.”
Dr. Paul Bradshaw, CEO of Inteligex, stated that
“Spinal cord injury is the single most expensive healthcare
condition in the world. I believe that a combinatorial
multi-faceted approach to treatment of chronic SCI like the one in
this project can both make a difference in patient’s lives and save
the healthcare system billions of dollars. Moreover, if the therapy
has an easy delivery method, we can expand to countries where there
is a massive barrier to any therapy or treatment and do a bit of
good for humanity.”
NurExone Announces Engagement Agreement
with bullVestor
The Company has entered into an agreement (the
“Agreement”) with bullVestor Medien GmbH
(“BullVestor”) to assist with and enhance
awareness of the Company’s products and services using advertising
and communications, some of which may constitute investor relations
activities pursuant to the policies of the TSX Venture Exchange.
The advertising and communications will occur in German-speaking
countries (Germany, Austria and Switzerland).
The Agreement is effective for four months from
the effective date and the total consideration payable to
BullVestor is CAD$300,000 on the effective date. The consideration
does not include any securities of the Company. BullVestor does not
have any interest, directly or indirectly, in the Company or its
securities, or any right or intent to acquire such an interest.
Aside from this engagement, the Company does not have any
relationship with BullVestor.
BullVestor is located in Austria.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided ExoTherapy to be delivered, non-invasively, to
patients who suffered traumatic spinal cord injuries. ExoTherapy
was conceptually demonstrated in animal studies at the Technion,
Israel Institute of Technology. NurExone is translating the
treatment to humans, and the company holds an exclusive worldwide
license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation -
CanadaPhone: +1 905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation -
GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements”, that reflect the Company’s current
expectations and projections about its future results. Wherever
possible, words such as “may”, “will”, “should”, “could”, “expect”,
“plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or
“potential” or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the collaboration project with Inteligex and the grant funding
pursuant thereto; the Agreement, the term of the Agreement and the
fees payable thereunder. These statements reflect management’s
current beliefs and are based on information currently available to
management as at the date hereof.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including the general business and economic conditions of the
industries and countries in which we operate, the general market
conditions, the ability to secure additional funding for the
collaboration with Inteligex and our ability to work
collaboratively with Inteligex.
Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company’s early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company’s
intellectual property, dependence on the Company’s strategic
partners and the risks discussed under the heading “Risk Factors”
on pages 29 to 36 of the Company’s Annual Information Form dated
March 30, 2023, a copy of which is available under the Company’s
SEDAR+ profile at www.sedarplus.ca. These factors should be
considered carefully and readers should not place undue reliance on
the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, the Company
cannot assure readers that actual results will be consistent with
these forward-looking statements. These forward-looking statements
are made as of the date of this press release, and the Company
assumes no obligation to update or revise them to reflect new
events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
From May 2024 to Jun 2024
Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
From Jun 2023 to Jun 2024